Proteome Sciences PLC (GB:PRM)
LSE:PRM

Proteome Sciences (PRM) Share Price & Analysis

1 Followers

PRM Stock Chart & Stats

Day’s Range0p - 0p
52-Week Range2.65p - 8.71p
Previous Close3.45p
Volume0.00
Average Volume (3M)165.84K
Market Cap
£10.18M
Enterprise Value18.10M
Total Cash (Recent Filing)£3.99M
Total Debt (Recent Filing)£11.91M
Price to Earnings (P/E)
Beta0.22
Apr 08, 2025
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding295,182,056
10 Day Avg. Volume348,155
30 Day Avg. Volume165,845
Standard Deviation0.16
R-Squared0.00077
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)-2.22
Price to Sales (P/S)354.04
Price to Cash Flow (P/CF)6.80
P/FCF Ratio4.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

37.47%0.00%0.00%62.53%
37.47%
Insiders
0.00% Other Institutional Investors
62.53% Public Companies and
Individual Investors

PRM FAQ

What was Proteome Sciences PLC’s price range in the past 12 months?
Proteome Sciences PLC lowest share price was 2.65p and its highest was 8.71p in the past 12 months.
    What is Proteome Sciences PLC’s market cap?
    Currently, no data Available
    When is Proteome Sciences PLC’s upcoming earnings report date?
    Proteome Sciences PLC’s upcoming earnings report date is Apr 08, 2025 which is in 254 days.
      How were Proteome Sciences PLC’s earnings last quarter?
      Currently, no data Available
      Is Proteome Sciences PLC overvalued?
      According to Wall Street analysts Proteome Sciences PLC’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Proteome Sciences PLC pay dividends?
        Proteome Sciences PLC does not currently pay dividends.
        What is Proteome Sciences PLC’s EPS estimate?
        Proteome Sciences PLC’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Proteome Sciences PLC have?
        Proteome Sciences PLC has 295,182,040 shares outstanding.
          What happened to Proteome Sciences PLC’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Proteome Sciences PLC?
          Currently, no hedge funds are holding shares in GB:PRM
          ---

          Proteome Sciences Stock Smart Score

          10
          Unlock Smart Score
          1
          2
          3
          4
          5
          6
          7
          8
          9
          10

          Technicals

          SMA
          Negative
          20 days / 200 days
          Momentum
          -54.15%
          12-Months-Change

          Fundamentals

          Return on Equity
          Trailing 12-Months
          Asset Growth
          -7.84%
          Trailing 12-Months

          Company Description

          Proteome Sciences PLC

          Proteome Sciences PLC is protein biomarker research and development. The company uses high sensitivity proprietary techniques to detect and characterize differentially expressed proteins in diseases for diagnostic, prognostic and therapeutic applications. Its only reportable segment is the sale of goods and biomarker services. It generates maximum revenue from the TMT product. Geographically, it has a presence in the United States, the United Kingdom, and the European Union.
          ---
          Similar Stocks
          Company
          Price & Change
          Follow
          Genus plc
          Oxford BioDynamics
          Omega Diagnostics
          Genedrive
          Popular Stocks
          ---
          What's Included in PREMIUM?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis